Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus METHYLPREDNISOLONE SODIUM SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus METHYLPREDNISOLONE SODIUM SUCCINATE.
CORTIFOAM vs METHYLPREDNISOLONE SODIUM SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Methylprednisolone sodium succinate is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; it also decreases cytokine production and immune cell activity.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Intravenous (IV) or intramuscular (IM) injection: 10-40 mg initially, then 10-40 mg every 6-12 hours. For pulse therapy: 1 g IV over 30 minutes daily for 3-5 days.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life: 2.5-3.5 hours (plasma); biological half-life: 12-36 hours (based on pharmacodynamic effects due to intracellular receptor binding and gene regulation)
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal: ~75% as metabolites (20-30% unchanged); Biliary/Fecal: minor (<10%)
Category C
Category D/X
Corticosteroid
Corticosteroid